{
    "id": 9981,
    "fullName": "FGFR2 - TACC3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-TACC3 results from the fusion of FGFR2 and TACC3, resulting in an oncogenic protein as demonstrated by ligand-independent phosphorylation, dimerization, and oncogenic transformation (PMID: 26048680).",
            "references": [
                {
                    "id": 3380,
                    "pubMedId": 26048680,
                    "title": "Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26048680"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - TACC3",
    "createDate": "08/04/2015",
    "updateDate": "05/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 10460,
                "geneSymbol": "TACC3",
                "terms": [
                    "TACC3",
                    "ERIC-1",
                    "ERIC1",
                    "maskin",
                    "Tacc4"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2676,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680).",
            "molecularProfile": {
                "id": 9979,
                "profileName": "FGFR2 - TACC3"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3380,
                    "pubMedId": 26048680,
                    "title": "Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26048680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20979,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Infigratinib (BGJ398) treatment induced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3 (PMID: 30067876).",
            "molecularProfile": {
                "id": 9979,
                "profileName": "FGFR2 - TACC3"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18217,
                    "pubMedId": 30067876,
                    "title": "HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30067876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2679,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680).",
            "molecularProfile": {
                "id": 9979,
                "profileName": "FGFR2 - TACC3"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3380,
                    "pubMedId": 26048680,
                    "title": "Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26048680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Infigratinib (BGJ398) and Ganetespib combination treatment led to enhanced apoptosis, and inhibited Fgfr and Erk phosphorylation, cell proliferation and tumor growth in a mouse cell line allograft model expressing FGFR2-TACC3 (PMID: 30067876).",
            "molecularProfile": {
                "id": 9979,
                "profileName": "FGFR2 - TACC3"
            },
            "therapy": {
                "id": 9530,
                "therapyName": "BGJ398 + Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18217,
                    "pubMedId": 30067876,
                    "title": "HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30067876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9979,
            "profileName": "FGFR2 - TACC3",
            "profileTreatmentApproaches": [
                {
                    "id": 7510,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 - TACC3"
                },
                {
                    "id": 7511,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 - TACC3"
                }
            ]
        },
        {
            "id": 31775,
            "profileName": "FGFR2 - CCDC6 FGFR2 - TACC3",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}